--- title: "EKSO Bionics | 10-K: FY2025 Revenue Misses Estimate at USD 12.8 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/276644049.md" datetime: "2026-02-23T21:09:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276644049.md) - [en](https://longbridge.com/en/news/276644049.md) - [zh-HK](https://longbridge.com/zh-HK/news/276644049.md) --- # EKSO Bionics | 10-K: FY2025 Revenue Misses Estimate at USD 12.8 M Revenue: As of FY2025, the actual value is USD 12.8 M, missing the estimate of USD 14.71 M. EPS: As of FY2025, the actual value is USD -4.91. EBIT: As of FY2025, the actual value is USD -13.02 M. #### Revenue Breakdown Ekso Bionics Holdings, Inc. reported device revenue of $9,241 thousand in 2025, a decrease from $13,323 thousand in 2024 . Service and support revenue was $2,918 thousand in 2025, compared to $3,121 thousand in 2024 . Subscription revenue decreased to $358 thousand in 2025 from $527 thousand in 2024, and parts and other revenue was $282 thousand in 2025, down from $954 thousand in 2024 . #### Geographic Revenue Revenue from the Americas decreased to $7,502 thousand in 2025 from $10,133 thousand in 2024, with the United States contributing $7,430 thousand in 2025 . EMEA revenue was $3,792 thousand in 2025, down from $5,942 thousand in 2024, while APAC revenue decreased to $1,505 thousand in 2025 from $1,850 thousand in 2024 . Sales denominated in foreign currencies represented approximately 42% of total revenue in 2025 . #### Gross Profit and Margin Gross profit decreased by 28% to $6,845 thousand in 2025 from $9,511 thousand in 2024 . The gross margin remained consistent at 53% for both 2025 and 2024 . #### Operating Expenses Sales and marketing expenses decreased by 2% to $7,154 thousand in 2025 from $7,308 thousand in 2024 . Research and development expenses decreased by 22% to $3,031 thousand in 2025 from $3,874 thousand in 2024 . General and administrative expenses increased by 14% to $9,986 thousand in 2025 from $8,789 thousand in 2024 . Total operating expenses increased by 1% to $20,171 thousand in 2025 compared to $19,971 thousand in 2024 . #### Operating and Net Loss Loss from operations increased by 27% to - $13,326 thousand in 2025 from - $10,460 thousand in 2024 . Net loss increased by 3% to - $11,695 thousand in 2025 from - $11,330 thousand in 2024 . #### Other Income (Expense), Net Total other income (expense), net, was $1,631 thousand in 2025, a significant change from - $870 thousand in 2024 . This included an unrealized gain on foreign exchange of $1,965 thousand in 2025, compared to an unrealized loss of - $965 thousand in 2024 . #### Impairment Losses Ekso Bionics Holdings, Inc. recorded an impairment loss of $570 thousand on a trade name intangible asset and an impairment loss of $180 thousand on an intellectual property asset in 2025 . #### Cash Flow and Liquidity Net cash used in operating activities increased to - $11,801 thousand in 2025 from - $9,846 thousand in 2024 . Net cash used in investing activities increased to - $188 thousand in 2025 from - $37 thousand in 2024 . Net cash provided by financing activities was $6,629 thousand in 2025, compared to $7,769 thousand in 2024 . Cash and restricted cash at year-end was $1,169 thousand in 2025, down from $6,493 thousand in 2024, and working capital decreased to $5.4 million in 2025 from $11.3 million in 2024 . #### Outlook / Guidance Ekso Bionics Holdings, Inc. anticipates that most of its 2026 revenue will come from Enterprise Health sales, with Personal Health product sales increasing quarter over quarter . The company expects to begin general commercialization of its Nomad product in late 2026, pending clinical and patient feedback . Additionally, the company is developing partnerships for its Personal Health market, with results expected in 2026 and beyond, and many claims anticipated to be submitted to CMS by partners within the next 12 months . ### Related Stocks - [EKSO.US](https://longbridge.com/en/quote/EKSO.US.md) - [CHRN.US](https://longbridge.com/en/quote/CHRN.US.md) ## Related News & Research - [External Review Highlights Broader Risk Exposure for Pinnacle West and APS Beyond 2025 10-K Disclosures](https://longbridge.com/en/news/285160175.md) - [Sirius XM Confirms No New Material Risks Since 2025 10-K, Reaffirming Existing SEC Disclosures](https://longbridge.com/en/news/284869645.md) - [Purple Innovation Reaffirms 2025 10-K Risk Factors, Warns of Broad Threats to Business and Stock Price](https://longbridge.com/en/news/284707881.md) - [Curbline Properties Signals Steady but Unchanged Risk Profile in Latest 10-K Filing](https://longbridge.com/en/news/284707205.md) - [Broadstone Net Lease Reaffirms 2025 10-K Risk Disclosures, Signals No Material Changes for Investors](https://longbridge.com/en/news/284957293.md)